• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在欧洲,患有内科疾病的患者的疾病负担和预防静脉血栓栓塞的未满足需求表明预防治疗的利用率不足。

Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies.

机构信息

BioMedCom Consultants Inc., 1405 TransCanada Highway, Suite 310, Montreal, Quebec H9P2V9, Canada.

出版信息

Thromb Haemost. 2011 Oct;106(4):600-8. doi: 10.1160/TH11-03-0168. Epub 2011 Aug 11.

DOI:10.1160/TH11-03-0168
PMID:21833448
Abstract

It was the aim of this review to assess the incidence of venous thromboembolism (VTE) and current practice patterns for VTE prophylaxis among medical patients with acute illness in Europe. A literature search was conducted on the epidemiology and prophylaxis practices of VTE prevention among adult patients treated in-hospital for major medical conditions. A total of 21 studies with European information published between 1999 and April 2010 were retrieved. Among patients hospitalised for an acute medical illness, the incidence of VTE varied between 3.65% (symptomatic only over 10.9 days) and 14.9% (asymptomatic and symptomatic over 14 days). While clinical guidelines recommend pharmacologic VTE prophylaxis for patients admitted to hospital with an acute medical illness who are bedridden, clear identification of specific risk groups who would benefit from VTE prophylaxis is lacking. In the majority of studies retrieved, prophylaxis was under-used among medical inpatients; 21% to 62% of all patients admitted to the hospital for acute medical illnesses did not receive VTE prophylaxis. Furthermore, among patients who did receive prophylaxis, a considerable proportion received medication that was not in accord with guidelines due to short duration, suboptimal dose, or inappropriate type of prophylaxis. In most cases, the duration of VTE prophylaxis did not exceed hospital stay, the mean duration of which varied between 5 and 11 days. In conclusion, despite demonstrated efficacy and established guidelines supporting VTE prophylaxis, utilisation rates and treatment duration remain suboptimal, leaving medical patients at continued risk for VTE. Improved guideline adherence and effective care delivery among the medically ill are stressed.

摘要

本综述旨在评估欧洲急性疾病住院患者静脉血栓栓塞症(VTE)的发生率和 VTE 预防的现行实践模式。对欧洲成年患者住院治疗主要内科疾病的 VTE 预防流行病学和预防措施进行了文献检索。共检索到 21 项 1999 年至 2010 年 4 月期间发表的欧洲信息研究,其中包括在急性内科疾病住院患者中,VTE 的发生率在 3.65%(仅在 10.9 天以上出现症状)至 14.9%(14 天以上无症状和有症状)之间变化。虽然临床指南建议对因急性内科疾病住院且卧床的患者进行药物性 VTE 预防,但缺乏明确的特定受益风险群体的识别。在检索到的大多数研究中,内科住院患者中预防措施的使用不足;21%至 62%的所有因急性内科疾病住院的患者未接受 VTE 预防。此外,在接受预防措施的患者中,由于持续时间短、剂量不足或预防类型不当,相当一部分患者接受的药物与指南不符。在大多数情况下,VTE 预防的持续时间不超过住院时间,住院时间的平均值在 5 至 11 天之间。总之,尽管 VTE 预防具有疗效,并且有既定的指南支持,但使用率和治疗持续时间仍然不理想,使内科患者持续面临 VTE 的风险。强调需要提高对内科患者的指南依从性和有效的医疗护理。

相似文献

1
Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies.在欧洲,患有内科疾病的患者的疾病负担和预防静脉血栓栓塞的未满足需求表明预防治疗的利用率不足。
Thromb Haemost. 2011 Oct;106(4):600-8. doi: 10.1160/TH11-03-0168. Epub 2011 Aug 11.
2
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.静脉血栓栓塞风险与住院内科患者的预防。ENDORSE 全球调查。
Thromb Haemost. 2010 Apr;103(4):736-48. doi: 10.1160/TH09-09-0667. Epub 2010 Feb 2.
3
Evaluation of the use of venous thromboembolism prophylaxis in hospitalised medical patients.住院内科患者静脉血栓栓塞症预防措施应用情况的评估
J R Coll Physicians Edinb. 2011 Dec;41(4):304-8. doi: 10.4997/JRCPE.2011.404.
4
A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.对出院后发生静脉血栓栓塞症的患者进行血栓预防治疗的回顾性研究。
N Z Med J. 2010 Feb 19;123(1309):37-49.
5
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients.真实世界中医疗住院患者静脉血栓栓塞症与抗栓预防的经济负担。
Thromb Res. 2013 Jan;131(1):17-23. doi: 10.1016/j.thromres.2012.10.008. Epub 2012 Nov 8.
6
A cross-sectional evaluation of venous thromboembolism risk and use of venous thromboembolism prophylaxis in hospitalized patients in Senegal.塞内加尔住院患者静脉血栓栓塞风险及预防的横断面评估。
Arch Cardiovasc Dis. 2011 Oct;104(10):493-501. doi: 10.1016/j.acvd.2011.05.007. Epub 2011 Sep 1.
7
Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline.澳大利亚医院住院患者静脉血栓栓塞症的预防:澳大利亚国家卫生和医学研究委员会临床实践指南概要。
Intern Med J. 2012 Jun;42(6):698-708. doi: 10.1111/j.1445-5994.2012.02808.x.
8
Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates.内科疾病患者的静脉血栓栓塞预防及提高预防率策略的制定。
Am J Hematol. 2005 Mar;78(3):167-72. doi: 10.1002/ajh.20281.
9
Venous thromboembolism following primary total hip arthroplasty.初次全髋关节置换术后的静脉血栓栓塞症
Int Angiol. 2009 Jun;28(3):215-21.
10
Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.医疗机构出院后癌症患者的静脉血栓栓塞症预防。
Am J Med. 2011 Dec;124(12):1143-50. doi: 10.1016/j.amjmed.2011.07.031.

引用本文的文献

1
Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm.窦性心律心力衰竭患者的抗血小板治疗与抗凝治疗对比
Cochrane Database Syst Rev. 2025 Jun 11;6(6):CD003333. doi: 10.1002/14651858.CD003333.pub4.
2
CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma.CiThro模型改善了无肝细胞癌的肝硬化住院患者症状性静脉血栓栓塞的预测。
United European Gastroenterol J. 2025 Jun;13(5):728-737. doi: 10.1002/ueg2.12758. Epub 2025 Jan 23.
3
Venous Thromboembolism Prophylaxis in Medical and Surgical Patients - What's Our Reality?
医疗和外科患者的静脉血栓栓塞预防——我们的实际情况如何?
Cureus. 2023 Nov 26;15(11):e49444. doi: 10.7759/cureus.49444. eCollection 2023 Nov.
4
A review of venous thromboembolism risk assessment models for different patient populations: What we know and don't!不同患者人群静脉血栓栓塞风险评估模型的综述:我们知道什么,不知道什么!
Medicine (Baltimore). 2023 Jan 13;102(2):e32398. doi: 10.1097/MD.0000000000032398.
5
Venous Thromboembolism Among Hospitalized Patients: Incidence and Adequacy of Thromboprophylaxis - A Retrospective Study.住院患者静脉血栓栓塞症:发生率和血栓预防的充分性——一项回顾性研究。
Vasc Health Risk Manag. 2022 Jul 24;18:575-587. doi: 10.2147/VHRM.S370344. eCollection 2022.
6
Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study.磺达肝癸钠和低分子肝素用于中国骨科大手术或创伤患者的静脉血栓栓塞症预防:一项真实世界研究。
BMC Surg. 2022 Jun 24;22(1):243. doi: 10.1186/s12893-022-01652-6.
7
Recommendations for VTE Prophylaxis in Medically Ill Patients.内科疾病患者静脉血栓栓塞症预防的建议
Ann Vasc Dis. 2020 Mar 25;13(1):38-44. doi: 10.3400/avd.ra.19-00115.
8
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.直接口服抗凝剂与传统抗凝剂在静脉血栓栓塞症中的安全性。
J Thromb Thrombolysis. 2019 Oct;48(3):439-453. doi: 10.1007/s11239-019-01878-x.
9
Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.肝病相关止血与血栓形成的概念与争议:第七届国际肝病凝血会议论文集
Thromb Haemost. 2018 Aug;118(8):1491-1506. doi: 10.1055/s-0038-1666861. Epub 2018 Jul 30.
10
Betrixaban for prevention of venous thromboembolism in acute medically ill patients.贝曲西班用于预防急性内科疾病患者的静脉血栓栓塞
Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi: 10.1093/eurheartj/suy017. Epub 2018 May 9.